609 articles
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
A completed trial examines how structured exercise reshapes body composition and sustains physical activity habits in breast cancer patients post-diagnosis.
A Phase 2 trial tests whether a fixed-dose combination pill can safely lower LDL cholesterol in people with type 2 diabetes.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
MD Anderson's Phase 1/2 trial explored injecting rituximab directly into spinal fluid to target CNS lymphoid malignancies.
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
Eli Lilly's phase 3 trial pits a novel weekly basal insulin against the gold-standard daily insulin degludec in type 1 diabetes patients.
A Phase 3 trial pits monthly lerodalcibep against evolocumab in homozygous familial hypercholesterolemia patients over 24 weeks.
A completed Danish trial investigates how blocking IL-6 signaling with tocilizumab alters fat, glucose, and protein metabolism in humans.
A prospective clinical study examines how gastric bypass alters gut bacteria, appetite hormones, and metabolic health in 60 severely obese patients.
A Danish case-control trial uses gold-standard metabolic testing to uncover how mtDNA mutations impair muscle glucose uptake and drive insulin resistance.
A Phase 2 open-label trial explores whether an approved immune drug can raise frataxin protein levels and slow neurological decline in Friedreich Ataxia.
